Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Success in research demands passion. It's crucial to find a subject that genuinely interests you and dedicate yourself to it. While there may be long periods where the efforts don't seem to yield desired or meaningful outcomes, perseverance is key. When success does come, it's a deeply rewarding experience. Hold onto that feeling.

Antineoplastic protein synthesis inhibitors are indicated for the treatment of chronic or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

I want us to disrupt the drug discovery and development process and to look at each place on the drug discovery and development pipeline, so that we can be much better at getting the right target, much quicker at getting the right compound and much more confident that those compounds have the right characteristics which mean they will be safe and well tolerated. Then we can go to the right patient population with the right dose, so we would have a much leaner, more successful process and be able to demonstrate the value of our AI technology.

The CAR positive rate is a critical metric for evaluating CAR-T product potency, directly influencing target recognition and cytotoxic efficacy. Monitoring CAR expression in peripheral blood or tissues post-infusion provides insights into in vivo expansion and persistence, informing treatment response, durability, and potential relapse risk. Dynamic CAR expression monitoring also helps assess immunogenicity and safety. Thus, a sensitive, reliable, and universal CAR detection system is vital for developing and evaluating CAR-T cell therapies. Currently, approved CAR-T products target CD19 or BCMA, making flow cytometry with recombinant BCMA or CD19 protein the standard detection method. Although highly specific, this approach is limited to single targets and is unsuitable for CAR-T screening and preclinical development. Several CAR detection methods have been developed, including Protein L (which binds immunoglobulins) or Fc-binding polyclonal antibodies. Protein L binds only to kappa light chains and fails to detect CARs containing lambda chains. Polyclonal antibodies may cross-react with patient IgG, causing false positives. Anti-idiotype antibodies offer high specificity and sensitivity by targeting unique idiotopes in the CAR's antigen-binding region, but they are challenging to develop and produce.

Exons are nucleotide sequences in DNA and RNA that are conserved in the creation of mature RNA. The process by which DNA is used as a template to create mRNA is called transcription. mRNA then works in conjunction with ribosomes and transfer RNA (tRNA), both present in the cytoplasm, to create proteins in a process known as translation. Exons usually include both the 5’- and 3’- untranslated regions of mRNA, which contain start and stop codons, in addition to any protein coding sequences.